Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 10:02 PM. | Search:

» StockRants Stock Forum » Public Stock Forums » Euro / UK Stock Picks » Strong Buy: ALTHX (MC $9 M) Alzheimer & Parkinson Data imminent



Reply
 
Thread Tools Search this Thread
Old 11-27-2019, 07:01 AM   Nav to Top  #1
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 263
Favorites: Aapl celg onxx
Rep Power: 107
Reputation: 36
Biohero is on a distinguished road
Default ALTHX (MC $9 M) Alzheimer & Parkinson Data imminent

Theranexus (ALTHX) Market Cap laughable $9 M /Cash $12.3 M / Shares Out 3.6 M/ Alzheimer P1b Data this Quarter /Parkinson P2 data in early Q1 2020 = Likely the CHEAPEST Alzheimer/ Parkinson stock on planet ...This could be more than just a potential 10 bagger


Alzheimer's disease-related neurocognitive disorders --The Phase 1b results are expected in Q4 2019.
excessive daytime sleepiness in Parkinson disease -- The Phase 2 results are expected in Q1 2020


Theranexus (Euronext: ALTHX) <<< French company

Market Cap: €8.73 M (~ US$ 9.62 M)
Cash €11.2 Million ( US$ 12.3 M )

Shares Out 3.6 Million


Homepage
https://www.theranexus.com/en/


https://www.theranexus.com/images/pd...lts_vFINAL.pdf


Drug Candidate THN102 –Parkinson's Disease and NarcolepsyOn 24 September, Theranexus announced the recruitment of its last patient with Parkinson's disease naive of any treatment for this pathology to its Phase II clinical trial which aims to evaluate the tolerance and efficacy of its drug candidate THN102 (modafinil/flecainide combination) on non-motor symptoms of the disease (drowsiness, attention and cognitive disorders).This triad, a major unmet medical need in the disease, has a very high market value potential (estimated at over $2 billion). The results for THN102 are expected in Q1 2020.

Drug Candidate THN201 –Completion of recruitment for the Phase Ib trial to treat Alzheimer's disease-related neurocognitive disorders On 17 September, Theranexus announced inclusion of the last healthy subject in its Phase Ib trial comparing the pharmacological efficacy of its drug candidate THN201 with the standard-of-care treatment in Alzheimer's disease-related neurocognitive disorders.The results are expected in Q4 2019.



Biohero is offline   Rate this post Yes | No Reply With Quote
Reply

Similar Threads
Thread Thread Starter Forum Replies Last Post
Buy: ACRS = MC$ 44 M /Cash $115 M / Phase 3 readout imminent Biohero US Stock Picks 16 10-11-2019 07:04 AM
Strong Buy: TBUFF (MC $23 M)Price 0.48 / 7 Big Drugs launched + Next Approval imminent= TGT $4-6 Biohero US Penny Stock Picks 0 03-18-2014 11:55 AM
Strong Buy: (INNV) MC $5 M /Float 3.3 M /2x Big Product Launchs imminent = 2000%++ Potential Biohero US Penny Stock Picks 1 09-24-2013 07:58 AM
Swine Flu - Pandemic Imminent inspirational Rumors & News 7 06-11-2009 03:57 PM
Alzheimer's Research aim2high Traders Lounge 0 05-08-2009 10:44 AM


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On